Skip to main content
. 2020 Jan 16;11:333. doi: 10.1038/s41467-019-14085-2

Fig. 1. Discovery of metastasis development (MetDev) genes.

Fig. 1

a Schematic depicting the experimental hypothesis: genes whose expression is upregulated in melanoblasts and metastatic melanoma, but downregulated in differentiated melanocytes (red line), may drive cellular functions that promote melanoma metastasis (MetDev genes). b Confocal imaging of iDct-GFP embryo at embryonic day 15.5 (E15.5) is magnification ×5, scale bars, 5 mm. c RNA-seq expression of mouse developing melanocytes: 467 embryo-specific genes shown. Black arrows: 42 genes identified from Cox proportional hazards model. Green arrows: genes functionally validated. Red arrow: Kdelr3. Kdelr3 validated both in Cox proportional hazards model and functionally validated. Embryonic days 15.5 and 17.5 (E15.5 and E17.5, respectively). Postnatal day 1 and postnatal day 7 (P1, P7, respectively). d RNA-seq expression of 46 genes in mouse developing melanocytes: Black text: 42 genes identified from Cox proportional hazards model. Red text: four genes functionally validated. Kdelr3 validated both in Cox proportional hazards model and functionally validated. e, f Cox proportional hazards modeling (GSE19234) yielded a 43-gene MetDev signature. Patients’ risk assessed in GSE8401 patient cohort. Late stage: stage III/IV metastatic melanomas. Early stage: stage I/II primary tumors. High expression: high expression of gene signature. Low expression: low expression of gene signature. Log-rank test. Late stage, high (N = 23) vs. low (N = 24), P = 3.486e − 05. Early stage, high (N = 14) vs. low (N = 13), P = 0.7655. c, d Color scales represent gene expression z scores.